CDNA CAREDX INC

CareDx Supports Launch of International COVID-19 Transplant Registry (C19TxR)

CareDx Supports Launch of International COVID-19 Transplant Registry (C19TxR)

CareDx works with International Consortium of Transplant Leaders on a Global Registry of Transplant Patients Diagnosed with COVID-19

SOUTH SAN FRANCISCO, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the COVID-19 Transplant Registry ().

With the COVID-19 pandemic, there is limited data on the impact on immunosuppressed transplant recipients who acquire the disease. CareDx is supporting the transplant community by running a registry through its OttrCare platform called C19TxR. The registry site will be free to use, open access, and web-based, with a real-time analytics dashboard for users to quickly engage in best practices for COVID-positive transplant patient management.

An international consortium has rapidly come together to centralize global data and insights on transplant patients with COVID-19. For centers interested in participating, go to C19TxR.org for more information.

“We need fast action to centralize and standardize our patient data across all centers in the US and abroad. This international COVID-19 transplant registry offers a unique capability to bring us together with OttrCare as a backbone for data capture and sharing,” said Hannah Valentine, MD, National Institutes of Health.

“An international consortium is critical to get insights on the transplant patient COVID cases. By combining our experiences, we will be able to better manage our patients through this unique and fast-changing pandemic,” said Vassilios Papalois, MD, President of the European Society of Transplantation (ESOT).

“It is great to see CareDx stepping up to help the community in this time of international crisis to support transplantation with C19TxR,” said Dorry Segev, MD PhD, Johns Hopkins. “We have a goal to bring standardization and individualization to transplantation through solutions, and creating a platform to share learnings for COVID-19 openly is essential to help us care for our patients,” said Jeremy Chapman, MD, Editor in Chief Transplantation Journals.

“International transplant clinicians are encouraged to submit patients through the brief data submission.  These data will be invaluable in identifying potential strategies to mitigate the impact of COVID-19 in solid organ transplant recipients,” said David Axelrod, MD MBA, Chairman Standards Committee American Society of Transplant Surgeons.

About CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit:

CONTACTS:

CareDx, Inc.

Sasha King

Chief Marketing Officer

415-287-2393

Investor Relations

Greg Chodaczek

646-924-1769

 

 

EN
06/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CAREDX INC

CareDx Inc: 1 director

A director at CareDx Inc sold 16,700 shares at 14.128USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell ...

CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation CareDx Expands Transplant Portfolio in Europe SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) --  CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT interpretation software for use in patients who have received hematopoieti...

 PRESS RELEASE

CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung...

CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the International Society for Heart and Lung Transplantation (ISHLT) has selected Dr. Berta Sáez-Gim...

 PRESS RELEASE

In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 o...

In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents Originally Asserted Against CareDx Natera Recycles Old IP for New Lawsuits SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Natera has just dropped one of their two patents originally asserted against CareDx. At the same time, Natera asserted two patents tha...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch